Literature DB >> 29929667

Harmful Effects of Exercise Intensity and Exercise Duration in Patients With Arrhythmogenic Cardiomyopathy.

Øyvind H Lie1, Lars A Dejgaard1, Jørg Saberniak2, Christine Rootwelt2, Mathis K Stokke3, Thor Edvardsen4, Kristina H Haugaa5.   

Abstract

OBJECTIVES: The goal of this study was to explore the association between exercise duration versus exercise intensity and adverse outcome in patients with arrhythmogenic cardiomyopathy (AC).
BACKGROUND: Vigorous exercise aggravates and accelerates AC, but there are no data assessing the harmful effects of exercise intensity and duration in these patients.
METHODS: Exercise habits at time of diagnosis were recorded by standardized interviews in consecutive AC patients. Exercise >6 metabolic equivalents was defined as high intensity, and exercise duration was categorized as long if above median. Life-threatening ventricular arrhythmia (VA) was defined as aborted cardiac arrest, documented sustained ventricular tachycardia, ventricular fibrillation, or appropriate implantable cardioverter-defibrillator therapy.
RESULTS: We included 173 AC patients (53% probands; 44% female; 41 ± 16 years of age). Median weekly exercise duration was 2.5 h (interquartile range: 2.0 to 5.5 h), and 91 patients (52%) reported high-intensity exercise. VA had occurred in 83 patients (48%) and was more prevalent in patients with high-intensity exercise than low-intensity exercise (74% vs. 20%, p < 0.001), and more prevalent in long-duration than short-duration exercise (65% vs. 31%, p < 0.001). High-intensity exercise was a strong and independent marker of VA, even when adjusted for the interaction with long-duration exercise (odds ratio: 3.8; 95% confidence interval: 1.3 to 11.0, p < 0.001), whereas long-duration exercise was not.
CONCLUSIONS: High-intensity exercise was a strong and independent marker of life-threatening VA in AC patients, independent of exercise duration. AC patients could be advised to restrict their exercise intensity.
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  arrhythmia; arrhythmogenic right ventricular cardiomyopathy; athletes heart; exercise intolerance; myocardial function; ventricular arrhythmia

Mesh:

Year:  2018        PMID: 29929667     DOI: 10.1016/j.jacep.2018.01.010

Source DB:  PubMed          Journal:  JACC Clin Electrophysiol        ISSN: 2405-500X


  20 in total

1.  The Brazilian Society of Cardiology and Brazilian Society of Exercise and Sports Medicine Updated Guidelines for Sports and Exercise Cardiology - 2019.

Authors:  Nabil Ghorayeb; Ricardo Stein; Daniel Jogaib Daher; Anderson Donelli da Silveira; Luiz Eduardo Fonteles Ritt; Daniel Fernando Pellegrino Dos Santos; Ana Paula Rennó Sierra; Artur Haddad Herdy; Claúdio Gil Soares de Araújo; Cléa Simone Sabino de Souza Colombo; Daniel Arkader Kopiler; Filipe Ferrari Ribeiro de Lacerda; José Kawazoe Lazzoli; Luciana Diniz Nagem Janot de Matos; Marcelo Bichels Leitão; Ricardo Contesini Francisco; Rodrigo Otávio Bougleux Alô; Sérgio Timerman; Tales de Carvalho; Thiago Ghorayeb Garcia
Journal:  Arq Bras Cardiol       Date:  2019-03       Impact factor: 2.000

Review 2.  Cardiac Imaging in the Athlete: Shrinking the "Gray Zone".

Authors:  Mario R Caruso; Lohit Garg; Matthew W Martinez
Journal:  Curr Treat Options Cardiovasc Med       Date:  2020-02-03

Review 3.  Role of Exercise as a Modulating Factor in Arrhythmogenic Cardiomyopathy.

Authors:  Alessandro Zorzi; Alberto Cipriani; Riccardo Bariani; Kalliopi Pilichou; Domenico Corrado; Barbara Bauce
Journal:  Curr Cardiol Rep       Date:  2021-05-07       Impact factor: 2.931

4.  Clinical and genetic features of arrhythmogenic cardiomyopathy: diagnosis, management and the heart failure perspective.

Authors:  Matteo Castrichini; Ramone Eldemire; Daniel W Groves; Matthew Rg Taylor; Shelley Miyamoto; Luisa Mestroni
Journal:  Prog Pediatr Cardiol       Date:  2021-11-02

5.  Genetic Variant Score and Arrhythmogenic Right Ventricular Cardiomyopathy Phenotype in Plakophilin-2 Mutation Carriers.

Authors:  Anneli Svensson; Pyotr G Platonov; Kristina H Haugaa; Wojciech Zareba; Henrik Kjærulf Jensen; Henning Bundgaard; Thomas Gilljam; Trine Madsen; Jim Hansen; Lars A Dejgaard; Lars O Karlsson; Anna Gréen; Bronislava Polonsky; Thor Edvardsen; Jesper Hastrup Svendsen; Cecilia Gunnarsson
Journal:  Cardiology       Date:  2021-09-01       Impact factor: 1.869

6.  Running the Risk: Exercise and Arrhythmogenic Cardiomyopathy.

Authors:  Lauren Eberly; Lohit Garg; Mahesh Vidula; Nosheen Reza; Sheela Krishnan
Journal:  Curr Treat Options Cardiovasc Med       Date:  2021-09-18

7.  Role of plakophilin-2 expression on exercise-related progression of arrhythmogenic right ventricular cardiomyopathy: a translational study.

Authors:  Marina Cerrone; Grecia M Marrón-Liñares; Chantal J M van Opbergen; Sarah Costa; Mimount Bourfiss; Marta Pérez-Hernández; Florencia Schlamp; Fabian Sanchis-Gomar; Kabir Malkani; Kamelia Drenkova; Mingliang Zhang; Xianming Lin; Adriana Heguy; Birgitta K Velthuis; Niek H J Prakken; Andre LaGerche; Hugh Calkins; Cynthia A James; Anneline S J M Te Riele; Mario Delmar
Journal:  Eur Heart J       Date:  2022-03-21       Impact factor: 35.855

Review 8.  Natural History of Arrhythmogenic Cardiomyopathy.

Authors:  Giulia Mattesi; Alessandro Zorzi; Domenico Corrado; Alberto Cipriani
Journal:  J Clin Med       Date:  2020-03-23       Impact factor: 4.241

Review 9.  Pregnancy in arrhythmogenic cardiomyopathy.

Authors:  Thomas Wichter; Peter Milberg; Henry D Wichter; Dirk G Dechering
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2021-05-25

10.  High penetrance and similar disease progression in probands and in family members with arrhythmogenic cardiomyopathy.

Authors:  Monica Chivulescu; Øyvind H Lie; Bogdan A Popescu; Helge Skulstad; Thor Edvardsen; Ruxandra O Jurcut; Kristina H Haugaa
Journal:  Eur Heart J       Date:  2020-04-07       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.